

Disclaimer: This is not the final version of the article. Changes may occur when the manuscript is published in its final format.

Targeted Cancer Therapy **Connect**

ISSN: 3104-4719

2025, Vol. 1, Cite as: doi:10.x/journal.x.x.x

 **SCIFINITI**
PUBLISHING

 **OPEN ACCESS**

Mini-Review

Covalent BH3-Mimetics and PROTACs Targeting BCL2 Family for Precision Apoptosis Induction

Abinash Nayak

Department of Zoology, Utkal University, Vani Bihar, Bhubaneswar – 751004, Odisha, India

email: abinashnayakzoology@gmail.com

<https://orcid.org/0009-0007-9351-9803>

Abstract

The BCL2 family of proteins serves as a central regulator of mitochondrial outer membrane permeabilization (MOMP) and intrinsic apoptosis, with anti-apoptotic members such as BCL2, BCL-XL, and MCL1 frequently overexpressed in cancers to evade programmed cell death. Traditional BH3 mimetics, like venetoclax and navitoclax, have revolutionized treatment for hematologic malignancies by competitively inhibiting these pro-survival proteins, yet they face challenges including acquired resistance, on-target toxicities and limited efficacy in solid tumors due to reversible binding and incomplete target engagement. To address these limitations, covalent BH3 mimetics—such as NA1-115-7 and drimane derivatives—emerge as irreversible inhibitors that enhance potency and duration of action, particularly against MCL1 and BCL-XL, by forming stable adducts at key residues like histidine or cysteine. Complementing this, proteolysis-targeting chimeras (PROTACs), exemplified by DT2216 (BCL-XL-specific) and 753B (dual BCL-XL/BCL2 degrader), leverage the ubiquitin-proteasome system for catalytic degradation, offering superior selectivity and reduced dosing frequency while mitigating platelet toxicity through E3 ligase choice. These strategies enable precision apoptosis induction by exploiting tumor-specific dependencies, biomarker-guided patient stratification and synergistic combinations with chemotherapies or immunotherapies. Preclinical data demonstrate enhanced tumor clearance in leukemia and solid tumor models, with clinical trials underway. Despite hurdles like PROTAC pharmacokinetics and covalent off-target reactivity, these innovations promise to expand BCL2-targeted therapies beyond hematologic cancers, fostering a new era of targeted apoptosis modulation in oncology. This Mini review synthesizes recent advances in targeting BH3 Mimetics accompanied by PROTAC for activating apoptosis in cancer cells. Furthermore, this explores the challenges in application of BH3 Mimetics in inducing apoptosis.

Keywords: cancer, apoptosis induction, BH3 mimetics, proteolysis-targeting chimeras (PROTACs), BCL2 proteins

1. Introduction

Apoptosis, or programmed cell death, is a tightly regulated process essential for tissue homeostasis, development, and elimination of damaged cells. Dysregulation of apoptosis underpins tumorigenesis, allowing cancer cells to survive genotoxic stresses, evade immune surveillance, and resist therapies. At the core of the intrinsic apoptosis pathway lies the BCL2 family, comprising over 20 members categorized by their BCL2-homology (BH) domains: anti-apoptotic proteins (BCL2, BCL-XL, BCL-w, MCL1, BFL1/A1) that inhibit MOMP, pro-apoptotic effectors (BAX, BAK) that permeabilize the mitochondrial membrane, and BH3-only sensitizers/activators (e.g., BIM, BID, PUMA, NOXA) that initiate the cascade by antagonizing anti-apoptotic counterparts (1). In cancer, amplification or overexpression of anti-apoptotic BCL2 family proteins confers survival advantages, making them prime therapeutic targets (2).

The paradigm-shifting discovery of BH3 mimetics—small molecules that emulate the BH3 α -helical domain to bind the hydrophobic groove of anti-apoptotic proteins—has validated pharmacological apoptosis induction. In 2002 Letai et al., demonstrated that BH3 domain can sensitize or activate mitochondrial apoptosis (3). Cory and Adams (2002) also reported about apoptosis regulation by BCL2 family proteins (4). Oltersdorf et al., 2005 reported about ABT-737 which is an inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w and have high affinity towards BH3 domain (5). Venetoclax, a BCL2-selective BH3 mimetic, garnered FDA approval in 2016 for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), achieving response rates exceeding 80% in combination regimens (6). However, non-covalent BH3 mimetics suffer from reversible engagement, necessitating high doses that exacerbate toxicities (e.g., navitoclax-induced BCL-XL-mediated platelet apoptosis) and foster resistance via compensatory upregulation of MCL1 or BCL-XL (7). Moreover, their efficacy wanes in solid tumors, where heterogeneous BCL2 dependencies and stromal barriers limit penetration.

Covalent BH3 mimetics and PROTACs revolutionize BCL2 family targeting: covalent inhibitors lock onto proteins for sustained inhibition, while PROTACs catalytically eliminate targets via ubiquitin-mediated degradation, achieving potent, precise apoptosis with minimal drug doses. These modalities promise precision apoptosis by tailoring degradation to tumor-specific proteomes, leveraging biomarkers like dynamic BH3 profiling for patient selection, and synergizing with DNA-damaging agents to lower apoptotic thresholds (6). This mini-review synthesizes recent advances in these technologies, their mechanisms, preclinical/clinical evidence, and translational potential for oncology.

2. BH3 Mimetics: Foundations and Limitations

BH3 mimetics competitively occupy the BH3-binding groove (encompassing P2-P4 pockets) of anti-apoptotic BCL2 proteins, displacing sequestered BIM or BID to liberate BAX/BAK oligomers for MOMP, cytochrome c release, and caspase activation (8). Structure-activity relationship (SAR) studies, guided by NMR and crystallography, yielded lead compounds such as ABT-737, a pan-inhibitor of BCL2, BCL-XL, and BCL-w with picomolar affinity (9).

Clinical translation accelerated with the orally bioavailable analog navitoclax (ABT-263), which demonstrated single-agent activity in CLL but was hampered by dose-limiting thrombocytopenia due to BCL-XL inhibition in platelets (10). Iterative optimization produced venetoclax (ABT-199), with >1,000-fold selectivity for BCL2 via a trifluoromethyl substitution that clashes with BCL-XL's Leu104, minimizing platelet effects (6). In the MURANO trial, venetoclax plus rituximab extended progression-free survival (PFS) to 53.6 months in relapsed CLL versus 9.4 months for rituximab alone (11). Similarly, in AML, venetoclax with azacitidine yielded 66.4% complete remission in elderly patients (VIALE-A trial) (6).

For MCL1, a short half-life (~30 min) protein pivotal in AML and multiple myeloma resistance, S63845 emerged as a selective inhibitor, synergizing with venetoclax in preclinical models but eliciting cardiac toxicities that halted its phase I trial (NCT03485596) (7). AZD5991 and AMG176, both macrocyclic MCL1 inhibitors, advanced to clinic but faced similar hurdles, underscoring the need for isoform-selective, low-toxicity agents (6).

There are still limitations. Reversible kinetics requires chronic exposure and thereby elicits acquired resistance through BCL2 mutations, such as G101V, or MCL1/BCL-XL upregulation, which is described in 20-30% of venetoclax-resistant CLL cases (12) In solid tumors, efficacy is rather poor, <20% response, due to low "mitochondrial priming" or sensitivity to BH3 peptides and poor pharmacokinetics (13). These gaps drive advances toward covalent and degradative modes. Several potency metrics are discussed in Table 1 (6,7, 14, 15).

Table 1: Potency Metrics for Key BH3 Mimetics and Derivatives

Compound	Target	Binding Affinity	Selectivity Index	References
Venetoclax	BCL2	0.020 nM	>1,000-fold vs. BCL-XL	(6)
S63845	MCL1	0.19 nM	High; cardiac risk	(7)
NA1-115-7	MCL1	0.28 μ M (EC50)	>10 (hematopoietic)	(14)
DT2216	BCL-XL	1.3 nM (DC50)	>100-fold platelet sparing	(15)

3. Covalent BH3 Mimetics: Irreversible Precision Targeting

Covalent BH3 mimetics transcend reversible inhibitors by electrophilically engaging nucleophilic residues (e.g., Cys, His) in the BH3 groove, yielding irreversible adducts that resist dissociation and amplify signaling duration. This "hit-and-run" strategy suits transient targets like MCL1, minimizing chronic exposure risks (16).

Pioneering work identified drimane sesquiterpenes from 'Zygogynum pancheri' as natural covalent BH3 mimetics (17). NA1-115-7, a drimane derivative, covalently binds MCL1's Cys245 via its α -methylene- γ -lactone, stabilizing an open conformation that disrupts BAK sequestration ($EC_{50}=0.28 \mu\text{M}$ in RS4;11 cells) and induces rapid BAX/BAK-dependent apoptosis in lymphoma xenografts without cardiotoxicity (14). Unlike S63845, NA1-115-7 spares normal hematopoietic cells (selectivity index >10), but its lipophilicity ($\log P=5.2$) and acid lability impede oral bioavailability; nanoemulsion formulations restore efficacy in vivo (tumor regression at 10 mg/kg) (17).

Extending to BCL-XL, drimane analogs like MIK- β covalently target Cys137, achieving dual MCL1/BCL-XL inhibition ($IC_{50}=0.5-1 \mu\text{M}$) in venetoclax-resistant AML models, where they restore BIM displacement and synergize with cytarabine (combination $CI<0.5$). Recent innovations harness histidine reactivity: aryl fluorosulfates (SuFEx chemistry) label MCL1's His224, yielding time-dependent inhibition ($k_{\text{inact}}/K_i=1.2\times 10^{-3} \text{ M}^{-1} \text{ s}^{-1}$) superior to reversible binders in Jurkat cells, with potential for photoactivatable variants to enhance spatial control (18).

Covalent advantages include "intrinsic selectivity" via differential residue accessibility—e.g., MCL1's solvent-exposed Cys vs. BCL2's buried equivalent—and prolonged pharmacodynamics ($t_{1/2} >24\text{h}$ post-washout), reducing dosing to intermittent schedules (19). As discussed preclinically, they excel in primed tumors: within MCL1-dependent multiple myeloma, NA1-115-7 achieves a 90% tumor burden reduction compared with 40% for S63845. Covalent liabilities, or so-called idiosyncratic toxicities and hERG off-targeting, necessitate cysteine/histidine mapping and warhead optimization. No covalent BH3 mimetics are in clinic, but phase I trials for MCL1-targeted acrylamides (e.g., BRD-810 analog) are anticipated by 2026, heralding precision via BH3 profiling to identify covalent-sensitive subsets (20).

4. PROTACs Targeting BCL2 Family: Degradative Apoptosis

PROTACs—heterobifunctional molecules comprising a target ligand, linker, and E3 ligase recruiter (e.g., VHL/Cereblon)—catalyze BCL2 family ubiquitination at lysine hotspots, funneling proteins to the 26S proteasome for irreversible degradation ($DC_{50}<10 \text{ nM}$, $D_{\text{max}}>90\%$) (21). Unlike inhibitors, PROTACs operate substoichiometrically, tolerate mutations, and exploit E3 expression gradients for tissue selectivity (e.g., low VHL in platelets spares BCL-XL toxicity) (6). BCL-XL PROTACs dominate: DT2216 (navitoclax-VHL chimera, PEG3 linker) degrades BCL-XL ($DC_{50}=1.3 \text{ nM}$ in MOLT-4 cells) with >100 -fold platelet sparing versus navitoclax, eradicating AML xenografts at 25 mg/kg BID without neutropenia (15). Phase I (NCT04860555) reports tolerability in solid tumors, with ongoing expansion in BCL-XL-high breast cancer. Dual degraders like 753B

(navitoclax-VHL, rigid piperazine linker) co-degrade BCL-XL ($D_{max}=95\%$) and inhibit BCL2 (non-degradative at $1\ \mu\text{M}$), eliminating 90% of leukemia blasts (MV4-11) and senescent cells post-chemotherapy, enhancing PFS in xenograft models ($HR=0.3$) (22). Its mechanism involves ternary complex formation ($K_d=12\ \text{nM}$), ubiquitin scanning, and proteasomal clearance, with minimal platelet impact (20% reduction at $10\ \mu\text{M}$ vs. 80% for navitoclax) (22).

For BCL2, selective PROTACs remain elusive due to groove rigidity; venetoclax-CRBN chimeras (e.g., PZ15227) yield dual BCL2/BCL-XL degradation ($DC_{50}=5\ \text{nM}$), potent in CLL ($EC_{50}=2\ \text{nM}$) but with modest selectivity (23). Recent efforts with IAP-recruiters (SMAC mimetic linker) achieved BCL2-specific $DC_{50}=18\ \text{nM}$ in RS4;11 cells, restoring apoptosis in venetoclax-resistant lines via neo-epitope exposure post-degradation (23). MCL1 PROTACs, like compound C5 (S63845-CRBN), degrade MCL1 ($D_{max}=85\%$) in 4 h, synergizing with venetoclax ($FI=0.1$) in myeloma, though cardiac liabilities persist (6). XZ338, a BCL-XL degrader (navitoclax-CRBN), boasts oral bioavailability ($F=42\%$) and brain penetration, active in glioblastoma models (tumor regression 70%) (24).

PROTACs enable precision by "hook effect" avoidance (optimal linker length 10-15 Å) and prodrug activation (e.g., tumor protease-cleavable masks), reducing systemic exposure (25). In SCLC, dual BCL-XL/BCL2 PROTACs like ARV-471 analogs overcome RB1 loss-mediated resistance, achieving 85% tumor kill (26). Challenges include large MW (>900 Da) hindering permeability and hook effects at high doses, addressed by truncated recruiters and lymphatic delivery. The figure 1 explains the mechanism of action of PROTAC mediated degradation of anti-apoptotic protein BCL2.




Figure 1: PROTAC contains a Protein binding domain and an Enzyme binding domain joined together by a Linker. PROTAC links the E3 ubiquitin ligase and BCL2 and BCL2 is ubiquitinated. The ubiquitinated BCL2 is degraded in 26S proteasome.

5. Comparative Landscape: Covalent BH3 Mimetics vs. PROTACs

Covalent BH3 mimetics and PROTAC degraders represent two distinct and emerging strategies for targeting anti-apoptotic BCL-2 family proteins to restore apoptosis in cancer cells. Although both classes aim to neutralize pro-survival proteins such as BCL-2, BCL-XL, and MCL1, they differ significantly in biochemical mechanism, pharmacology, resistance profile, and clinical readiness. The Table 2 below presents the comparative analysis of Covalent BH3 Mimetics and PROTAC Degraders towards apoptosis (10, 16, 18, 22, 27).

Table 2: Comparative Overview of Covalent BH3 Mimetics and PROTACs Targeting BCL2 Family

Feature	Covalent BH3 Mimetics	PROTAC Degraders	References
Mechanism	Irreversible inhibition of anti-apoptotic BCL2 proteins through covalent bonding to residues such as Cys245 or His224	Catalytic ubiquitin-dependent degradation via ternary complex formation with E3 ligases such as VHL or CRBN	(22)
Duration	Long-lasting inhibition due to irreversible adduct formation, enabling prolonged MCL1/BCL-XL suppression	Duration depends on proteasomal turnover rate and E3 ligase recycling	(18)
Overcoming resistance	Partially effective; sensitive to mutations in BH3-binding groove and compensatory MCL1/BCL-XL upregulation	Strong; bypasses point mutations and overcomes adaptive resistance via complete protein degradation	(16)
Platelet toxicity	BCL-XL covalent inhibitors may still induce platelet	VHL-recruiting degraders (e.g., DT2216) spare	(27)

	apoptosis due to BCL-XL dependence	platelets due to low VHL expression	
Challenges	Off-target reactivity, limited oral bioavailability, warhead instability and delivery issues	High molecular weight, poor permeability, immunogenicity risks, hook effect	(10)
Clinical status	Preclinical/early development; no covalent BH3 mimetic yet in clinical trials	Multiple degraders (e.g., DT2216, 753B) in Phase I/II clinical trials.	(27)

6. Precision Apoptosis Induction: Clinical Translation and Synergies

Precision hinges on dissecting BCL2 dependencies via BH3 profiling—ex vivo peptide exposure revealing priming scores (>50% cytochrome c release predicts response)—stratifying patients for covalent/PROTAC trials (28). In CLL, venetoclax priming correlates with PFS (HR=0.4), guiding MCL1 co-targeting (6). NA1-115-7 sensitizes low-primed solid tumors (e.g., ovarian, priming=20%) by sustained MCL1 blockade, yielding 60% apoptosis in patient-derived xenografts (14).

PROTAC753B clears therapy-induced senescent cells (SASPs drivers of relapse), boosting doxorubicin efficacy in AML (tumor-free survival >60 days) (22). DT2216 + PD-1 blockade—enhance T-cell infiltration by apoptotic efferocytosis, doubling responses in NSCLC models (11). Biomarker panels integrating proteomics (MCL1/BCL-XL ratio) and genomics (BCL2 amplification) will refine cohorts, as in ongoing DT2216 expansion (NCT04860555) (29).

Toxicity mitigation via platelet-sparing (VHL PROTACs) and cardiac monitoring (troponin for MCL1) is pivotal. Covalent warheads require GSH competition assays for safety (6). In solid tumors, intratumoral priming via metabolic stressors (e.g., glutaminase inhibitors) primes for BH3 modalities, as in TNBC where MCL1 addiction yields 75% regression with drimanes + carboplatin (30). The below Table 3 describes about the clinical trials for for BH3 Mimetics and PROTACs (31-34).

Table 3: Summary of Ongoing Clinical Trials for BH3 Mimetics and PROTACs

Agent	Target	Phase	Type(s)	Key Outcomes/Status	NCT Identifier	Reference
Venetoclax	BCL2	III	AML/CLL	66.4% CR in elderly AML	NCT03467199	(31)

				(VIALE-A); PFS 53.6 mo (MURANO)		
S63845	MCL1	II	AML/MM	Halted due to cardiac toxicity; 20% ORR in MM	NCT03485596	(32)
AZD5991	MCL1	I/II	Solid tumors	Dose-limiting cardiac events; modest responses	NCT03218683	(32)
DT2216	BCL-XL	I	Solid/AML	Tolerable; expansions in BCL- XL-high breast; no thrombocytopenia	NCT04886622	(33)
ABBV-467	MCL1	I	MM/NHL	Troponin elevations; antitumor activity in MM	NCT05730181	(34)

7. Challenges

Achieving selective inhibition or degradation of specific BCL-2 family members remains a primary obstacle. On-target toxicities pose a significant barrier, particularly for multi-family targeting. Acquired resistance undermines long-term efficacy. In covalent BH3-mimetics, point mutations in the BH3-binding groove (e.g., G101V in BCL-2) or upregulation of compensatory anti-apoptotics like BCL-XL reduce binding affinity, mirroring resistance patterns observed with non-covalent venetoclax. The structural demands of these agents hinder clinical translation. Covalent BH3-mimetics often violate Lipinski's rule of five due to their bulky warheads and linkers, leading to poor oral bioavailability and rapid clearance, as highlighted by the need for nanoemulsion formulations of NA1-115-7 to enhance tumor penetration (6). For PROTACs, chronic exposure leads to genomic alterations in E3 ligase components, such as CRBN mutations, that impede ternary complex formation and degradation, as modeled in BET-PROTAC systems adaptable to BCL-2 contexts. (27). Covalent BH3 mimetics must contend with warhead reactivity, including

thiol trapping, and delivery; future generations may utilize bioorthogonal click chemistry for in situ activation. (35). PROTACs face ADME challenges-including low solubility and efflux-but lymphatic-optimized linkers and oral CRBN variants, including XZ338, continue to advance pipelines. (35) Resistance due to UPS adaptation, including PSMB5 upregulation, may be mitigated through the use of HDAC6 inhibitors to enhance aggresome clearance.

Acquired resistance to BH3 mimetics via BCL2 mutations (e.g., G101V) or MCL1 upregulation occurs in 20-30% of cases. Apart from PROTACs, other strategies include BH3 switching, such as venetoclax to MCL1 inhibitors, and combinatorials: sabutoclax is a pan-BH3 mimetic which synergizes with docetaxel, underlining precision via BH3 profiling. (36). Combinatorial BH3 approaches mitigate resistance and extend tumor clearance by 60% in models (7).

Despite the great promise of PROTACs against the BCL2 family for precision apoptosis induction, a series of underexplored limitations is generally restricting their broader clinical successes, especially in solid tumors. The immunogenicity due to the large heterobifunctional structure of PROTACs can cause anti-drug antibodies or anti-PEG antibodies and initiate adaptive immune responses, as observed across preclinical and early clinical studies in multiple PROTAC scaffolds (37,38). TME barriers significantly hinder the efficacy of PROTACs in solid tumors: hypoxia, dense stroma, and high interstitial fluid pressure hamper tumor penetration and retention, leading to a deficiency in intracellular concentrations required for effective ternary complex formation; hypoxia-activated or nanoparticle-encapsulated BCL-XL PROTACs have thus been developed to partially surmount these barriers, although stromal sequestration still limits target engagement in breast and pancreatic cancer models (39, 40). Finally, pharmacodynamic complexities arise from variable ternary complex stability, E3 ligase expression heterogeneity, and the “hook effect” at higher doses, leading to non-linear degradation kinetics and unpredictable BCL2-family protein depletion in patients (41,42). Addressing these challenges through next-generation delivery systems, immune-silent linkers, and patient-stratified dosing regimens will be essential to translate the full potential of BCL2-targeted PROTACs into durable clinical responses.

However, there are some controversies exists in the field of research. Some studies show that blocking MCL1 quickly causes heart damage to heart muscle cells, which is why several clinical trials of MCL1 inhibitors (S63845, AZD5991, AMG176) were stopped or heavily dose-limited because of elevated troponin levels in patients. However, other groups report that newer MCL1-targeted compounds (e.g., shorter-acting or more selective molecules) do not harm the heart in animal models and suggest that the toxicity may be manageable with intermittent dosing or cardiac monitoring (6). The field has not yet reached agreement on whether MCL1 can be safely drugged in humans. Although PROTACs are designed to remove only the intended BCL2-family protein, several reports show they can accidentally degrade other proteins or trigger immune reactions against the PROTAC molecule itself. At the same time, some researchers argue that these off-target events are rare and usually harmless, especially when VHL is used as the E3 ligase. This disagreement makes clinicians cautious about long-term PROTAC use, particularly in patients who need many months of treatment (43).

8. Conclusion and Future direction

Despite significant advancements in covalent BH3 mimetics and PROTACs for targeting the BCL2 family, several research gaps persist that hinder their full clinical potential. This review has pointed out several research gaps in understanding the mechanisms of resistance, biomarker development for diagnostic purposes, and also the role of less known BH3 family proteins such as BCL2A1 or BFK in apoptosis. A primary gap exists in the basic understanding of the mechanisms of resistance, particularly in solid tumors, in which BH3 mimetics have shown modest efficacy because of heterogeneous dependencies and because BCL2 family RNA expression has a poor correlation with sensitivity. The role of compensatory upregulation of MCL1/BCL-XL and non-canonical BCL2 functions remains underexplored. Covalent inhibitors, while promising for prolonged engagement, face gaps in warhead selectivity because off-target reactivity to non-cysteine residues risks idiosyncratic toxicities and inadequate pharmacokinetic profiles in vivo. PROTACs, though catalytic and platelet-sparing, suffer from large molecular weights >900 Da, impeding oral bioavailability and brain penetration, alongside undefined "hook effects" at high doses and UPS adaptation in resistant cells.

Another important gap is biomarker development: whereas BH3 profiling predicts priming, its standardization for covalent/PROTAC responses is lagging, and genomic complexity—for example, TP53 and NOTCH1 mutations—only partially correlates with outcomes. Lastly, the relative resistance mediated by understudied and less commonly targeted BCL2 family members, such as BCL2A1 or BFK, speaks to the need for isoform-specific, comprehensive targeting. These issues are further compounded in solid tumors, where stromal barriers and generally low mitochondrial priming limit translation from hematologic successes.

To bridge these gaps, future directions should prioritize innovative modalities and combinations for enhanced precision. Multi-valent PROTACs co-degrading BCL2/MCL1/BCL-XL, guided by AI-driven linker design, promise pan-inhibition without toxicities like cardiac effects from MCL1 blockers. Biomarker-guided strategies, integrating proteomics with dynamic BH3 profiling, will enable patient stratification, as piloted in venetoclax trials. Beyond oncology, applications in senescence clearance and neurodegeneration represent untapped avenues. Developing AI and computational tools for precision drug targeting can open new doors for cancer eradication in future.

The next decade of BCL2-family-targeted therapy should follow a clear, prioritized roadmap to translate covalent BH3 mimetics and PROTACs from promising preclinical tools into broadly effective medicines, particularly for solid tumors. Firstly, resistance-proof multi-modal degraders must be developed. Tumor-microenvironment-responsive delivery platforms are urgently needed. Hypoxia- or protease-activatable PROTACs, nanoparticle-encapsulated covalent mimetics, and lymphatic-targeted formulations may overcome stromal barriers and poor penetration that currently limit efficacy in pancreatic, ovarian, and triple-negative breast cancers. Next-generation biomarkers beyond static BH3 profiling such as real-time proteomic monitoring of BCL2-family stoichiometry, E3 ligase expression mapping, and liquid-biopsy detection of

circulating ubiquitin-tagged fragments, and machine-learning integration of genomic and metabolic signatures will enable precise patient stratification and adaptive dosing. Addressing these will propel precision apoptosis induction, transforming outcomes in BCL2-driven cancers in future.

List of abbreviations

PROTAC= Proteolysis-targeting chimeras

BCL2= B-Cell Lymphoma2

MCL1= Myeloid Cell Leukemia 1

BH3= BCL2 Homology 3

AML= Acute Myeloid Leukemia

BCL-XL= B-Cell Lymphoma-extra large

NOTCH1= Neurogenic locus notch homolog protein 1

TME = Tumor Microenvironment

Author Contributions:

The author is solely responsible for conceptualization, investigation, writing – original draft, writing – review and editing, and visualization of the manuscript.

Funding: No fund has been received for preparation of this manuscript.

Conflict of Interest:

The author declares no conflicts of interest.

Acknowledgment

“Grammarly web portal” has been used for language correction. No other AI Tools has been used for Data Generation. I acknowledge Biorender.com for image generation.

REFERENCES

1. Roberts AW, Huang DCS. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell

- Malignancies. *Clin Pharmacol Ther* [Internet]. 2016 Jan 1 [cited 2025 Sep 28];101(1):89. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5657403/>
2. Delbridge ARD, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. *Cell Death Differ* [Internet]. 2015 Jul 9 [cited 2025 Sep 28];22(7):1071–80. Available from: <https://www.nature.com/articles/cdd201550>
 3. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. *Cancer Cell* [Internet]. 2002 [cited 2025 Nov 23];2(3):183–92. Available from: <https://pubmed.ncbi.nlm.nih.gov/12242151/>
 4. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. *Nat Rev Cancer* [Internet]. 2002 Sep [cited 2025 Nov 23];2(9):647–56. Available from: <https://pubmed.ncbi.nlm.nih.gov/12209154/>
 5. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* [Internet]. 2005 Jun 2 [cited 2025 Nov 23];435(7042):677–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/15902208/>
 6. Vogler M, Braun Y, Smith VM, Westhoff MA, Pereira RS, Pieper NM, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. *Signal Transduct Target Ther* [Internet]. 2025 Dec 1 [cited 2025 Sep 28];10(1):1–31. Available from: <https://www.nature.com/articles/s41392-025-02176-0>
 7. Townsend PA, Kozhevnikova M V., Cexus ONF, Zamyatnin AA, Soond SM. BH3-mimetics: recent developments in cancer therapy. *Journal of Experimental and Clinical Cancer Research* [Internet]. 2021 Dec 1 [cited 2025 Sep 28];40(1):1–33. Available from: <https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02157-5>
 8. Billard C. BH3 mimetics: Status of the field and new developments. *Mol Cancer Ther* [Internet]. 2013 Sep 1 [cited 2025 Sep 28];12(9):1691–700. Available from: [/mct/article/12/9/1691/91693/BH3-Mimetics-Status-of-the-Field-and-New](https://mct/article/12/9/1691/91693/BH3-Mimetics-Status-of-the-Field-and-New)
 9. Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. *Cancer Cell* [Internet]. 2018 Dec 10 [cited 2025 Sep 28];34(6):879–91. Available from: <https://www.sciencedirect.com/science/article/pii/S1535610818305257>
 10. Ludwig LM, Nassin ML, Hadji A, LaBelle JL. Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation. *Front Pediatr* [Internet]. 2016 Dec 1 [cited 2025 Sep 28];4(DEC):135. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5174130/>
 11. Alharbi F, Almanifi E, Ashrafuzzaman M. Targeting BCL-2 family proteins using BH3 mimetic drugs for cancer therapy: A systematic review of randomized clinical trials. *Med Drug Discov* [Internet]. 2024 Dec 1 [cited 2025 Sep 28];24:100199. Available from: <https://www.sciencedirect.com/science/article/pii/S2590098624000241>
 12. Smith VM, Dietz A, Henz K, Bruecher D, Jackson R, Kowald L, et al. Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. *Haematologica* [Internet]. 2020 Aug 1 [cited 2025 Sep 28];105(8):2150–63. Available from: <https://haematologica.org/article/view/9988>

13. Kehr S, Vogler M. It's time to die: BH3 mimetics in solid tumors. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* [Internet]. 2021 Apr 1 [cited 2025 Sep 28];1868(5):118987. Available from: <https://www.sciencedirect.com/science/article/pii/S0167488921000410>
14. Daressy F, Séguy L, Favre L, Corvaisier S, Apel C, Groo AC, et al. NA1—115—7, from *Zygygynum pancheri*, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes. *Biomedicine & Pharmacotherapy* [Internet]. 2022 Oct 1 [cited 2025 Sep 28];154:113546. Available from: <https://www.sciencedirect.com/science/article/pii/S0753332222009350>
15. Skwarska A, Konopleva M. BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs. *Cancer Res* [Internet]. 2023 Nov 1 [cited 2025 Sep 28];83(21):3501–3. Available from: [/cancerres/article/83/21/3501/729709/BCL-xL-Targeting-to-Induce-Apoptosis-and-to](https://www.aacr.org/journal/cancerres/article/83/21/3501/729709/BCL-xL-Targeting-to-Induce-Apoptosis-and-to)
16. Cerella C, Dicato M, Diederich M. BH3 Mimetics in AML Therapy: Death and Beyond? *Trends Pharmacol Sci* [Internet]. 2020 Nov 1 [cited 2025 Sep 30];41(11):793–814. Available from: <https://www.sciencedirect.com/science/article/pii/S0165614720302108>
17. Daressy F, Malard F, Seguy L, Guérineau V, Apel C, Dumontet V, et al. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1. *ChemMedChem* [Internet]. 2021 Jun 7 [cited 2025 Sep 30];16(11):1789–98. Available from: [/doi/pdf/10.1002/cmdc.202100011](https://doi.org/10.1002/cmdc.202100011)
18. Alboreggia G, Udompholkul P, Atienza EL, Muzzarelli K, Assar Z, Pellicchia M. Covalent Targeting of Histidine Residues with Aryl Fluorosulfates: Application to Mcl-1 BH3 Mimetics. *J Med Chem* [Internet]. 2024 Nov 28 [cited 2025 Sep 28];67(22):20214–23. Available from: [/doi/pdf/10.1021/acs.jmedchem.4c01541?ref=article_openPDF](https://doi.org/10.1021/acs.jmedchem.4c01541?ref=article_openPDF)
19. Lessene G. Close encounter of the covalent kind: Inhibiting MCL1's proapoptotic activity with covalent inhibitors. *Cell Death Discov* [Internet]. 2017 [cited 2025 Sep 28];3:16094. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5253618/>
20. Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. *Nat Cancer* [Internet]. 2024 Oct 1 [cited 2025 Sep 28];5(10):1479–93. Available from: <https://www.nature.com/articles/s43018-024-00814-0>
21. Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, et al. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,. *Nat Commun* [Internet]. 2021 Dec 1 [cited 2025 Sep 28];12(1):1–14. Available from: <https://www.nature.com/articles/s41467-021-27210-x>
22. Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, et al. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. *Haematologica* [Internet]. 2023 Apr 20 [cited 2025 Sep 28];108(10):2626–38. Available from: <https://haematologica.org/article/view/haematol.2022.281915>

23. Bricelj A, Dora Ng YL, Gobec M, Kuchta R, Hu W, Javornik Š, et al. Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs. *Chemistry – A European Journal* [Internet]. 2024 Aug 12 [cited 2025 Sep 28];30(45):e202400430. Available from: [/doi/pdf/10.1002/chem.202400430](https://doi.org/10.1002/chem.202400430)
24. Zhang X, Thummuri D, Hu W, Liu X, Zhang P, Zhou S, et al. Discovery of XZ338, a highly potent BCL-XL degrader. *Eur J Med Chem* [Internet]. 2025 Jul 5 [cited 2025 Sep 28];291:117624. Available from: <https://www.sciencedirect.com/science/article/abs/pii/S0223523425003897>
25. Kargbo RB. PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment. *ACS Med Chem Lett* [Internet]. 2023 May 11 [cited 2025 Sep 28];14(5):541–2. Available from: [/doi/pdf/10.1021/acsmedchemlett.3c00113?ref=article_openPDF](https://doi.org/10.1021/acsmedchemlett.3c00113?ref=article_openPDF)
26. Khan S, Cao L, Wiegand J, Zhang P, Zajac-Kaye M, Kaye FJ, et al. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. *Cells* [Internet]. 2024 Mar 1 [cited 2025 Sep 28];13(6). Available from: <https://pubmed.ncbi.nlm.nih.gov/38534371/>
27. Zhang P, Zhang X, Liu X, Khan S, Zhou D, Zheng G. PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors. *Explor Target Antitumor Ther* [Internet]. 2020 [cited 2025 Nov 23];1(4):259–72. Available from: <https://pubmed.ncbi.nlm.nih.gov/34296214/>
28. Gomez-Bougie P, Maiga S, Tessoulin B, Bourcier J, Bonnet A, Rodriguez MS, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. *Blood* [Internet]. 2018 Dec 20 [cited 2025 Sep 28];132(25):2656–69. Available from: <https://dx.doi.org/10.1182/blood-2018-03-836718>
29. He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, et al. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. *J Hematol Oncol* [Internet]. 2020 Jul 16 [cited 2025 Sep 30];13(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/32677976/>
30. López J, Llop-Hernández À, Verdura S, Serrano-Hervás E, Martinez-Balibrea E, Bosch-Barrera J, et al. Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies. *Cell Death Discov* [Internet]. 2025 Dec 1 [cited 2025 Sep 28];11(1):1–16. Available from: <https://www.nature.com/articles/s41420-025-02379-y>
31. Mukherjee N, Sheetz J, Shellman YG. Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies. *International Journal of Molecular Sciences* 2025, Vol 26, Page 9859 [Internet]. 2025 Oct 10 [cited 2025 Nov 23];26(20):9859. Available from: <https://www.mdpi.com/1422-0067/26/20/9859/htm>
32. Mahmoud N, Qin X, Bzeih W, Khabibullin D, Alchoueiry M, Safi S, et al. BCL-xL dependency in chromophobe renal cell carcinoma. *Cancer Gene Therapy* 2025 32:10 [Internet]. 2025 Aug 16 [cited 2025 Nov 23];32(10):1133–43. Available from: <https://www.nature.com/articles/s41417-025-00953-1>
33. Varkaris A, Wang K, Nouri M, Kozlova N, Schmidt DR, Stavridi A, et al. BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress. *Nature*

- Communications 2025 16:1 [Internet]. 2025 May 28 [cited 2025 Nov 23];16(1):4931-. Available from: <https://www.nature.com/articles/s41467-025-60238-x>
34. Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. *Communications Medicine* [Internet]. 2023 Dec 1 [cited 2025 Nov 23];3(1):154-. Available from: <https://www.nature.com/articles/s43856-023-00380-z>
 35. Nayak D, Lv D, Yuan Y, Zhang P, Hu W, Nayak A, et al. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. *Nat Commun* [Internet]. 2024 Dec 1 [cited 2025 Sep 29];15(1):1–17. Available from: <https://www.nature.com/articles/s41467-024-46922-4>
 36. Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. *Cancer Cell* [Internet]. 2020 Dec 14 [cited 2025 Nov 28];38(6):872. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7988687/>
 37. Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. *Nat Rev Drug Discov* [Internet]. 2022 Mar 1 [cited 2025 Nov 23];21(3):181–200. Available from: <https://pubmed.ncbi.nlm.nih.gov/35042991/>
 38. Shi J, Wang L, Zeng X, Xie C, Meng Z, Campbell A, et al. Precision-engineered PROTACs minimize off-tissue effects in cancer therapy. *Front Mol Biosci* [Internet]. 2024 [cited 2025 Nov 23];11:1505255. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11621628/>
 39. Wang C, Zhang Y, Chen W, Wu Y, Xing D. New-generation advanced PROTACs as potential therapeutic agents in cancer therapy. *Mol Cancer* [Internet]. 2024 Dec 1 [cited 2025 Nov 23];23(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/38773495/>
 40. Gao J, Jiang X, Lei S, Cheng W, Lai Y, Li M, et al. A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy. *Nat Commun* [Internet]. 2024 Dec 1 [cited 2025 Nov 23];15(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/39098906/>
 41. Haid RTU, Reichel A. A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs). *Pharmaceutics* [Internet]. 2023 Jan 1 [cited 2025 Nov 23];15(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/36678824/>
 42. Casan JML, Seymour JF. Degradable upgraded: the rise of PROTACs in hematological malignancies. *Blood* [Internet]. 2024 Mar 28 [cited 2025 Nov 23];143(13):1218–30. Available from: <https://dx.doi.org/10.1182/blood.2023022993>
 43. Liu Z, Zhang Y, Xiang Y, Kang X. Small-Molecule PROTACs for Cancer Immunotherapy. *Molecules* [Internet]. 2022 Sep 1 [cited 2025 Nov 28];27(17):5439. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9458232/>